Efficacy and safety of adjuvant recombinant human erythropoietin and ferrous sulfate as treatment for iron deficiency anemia during the third trimester of pregnancy

2016 ◽  
Vol 205 ◽  
pp. 32-36 ◽  
Author(s):  
Luis Rodrigo Sanchez-Gonzalez ◽  
Simón Enrique Castro-Melendez ◽  
Alejandra Cristina Angeles-Torres ◽  
Nohemi Castro-Cortina ◽  
Alfredo Escobar-Valencia ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Recombinant Human Erythropoietin ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Third Trimester ◽  
The Third ◽  
Human Erythropoietin

scholarly journals Analysis of the iron profile and the incidence of iron deficiency anemia in the third-trimester pregnant women in the coendemic areas of Bengkulu City, Indonesia

2019 ◽  
Author(s):  
Mohammad Zulkarnain ◽  
Rizka Muliani ◽  
Rico Januar Sitorus ◽  
Nurlaili Nurlaili
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Total Sample ◽  
Deficiency Anemia ◽  
P Value ◽  
Binary Logistic Regression Analysis ◽  
Third Trimester ◽  
Cross Sectional ◽  
The Third

Pregnant women are at risk for iron deficiency anemia especially pregnant women in malaria-endemic areas. This study aimed to analyze the profile of iron in the third trimester pregnant women with iron deficiency anemia in co-endemic area of Bengkulu city. This study was cross-sectional study with a total sample of 66 pregnant women who met the inclusion criteria. Examination profile of iron in pregnant women is done by taking blood specimen through the vena cubity. Profile iron includes examination sTfR levels, hepcidin, transferrin were examined by ELISA. Determination of iron deficiency anemia is based on the results of Hb, serum iron and TIBC. The results showed 39.4% of pregnant women experience iron deficiency anemia. There is an average difference between hepcidin levels with the incidence of iron deficiency anemia (p-value 0.031). Based on binary logistic regression analysis profile iron with irondeficiency anemia in pregnant women, hepcidin levels are predictors factors on the incidence of iron deficiency anemia (p-value 0.000, 95% CI .296-.709).

scholarly journals The Efficacy of Recombinant Human Erythropoietin in Pregnant Patients with Iron Deficiency Anemia

2018 ◽  
Vol 86 (9) ◽  
pp. 2947-2952
Author(s):  
LAMIAA M. AL-AHWAL, M.D.; SAHAR M. HAZZAA, M.D. ◽  
ABD EL-GAFAR S. DAWOOD, M.D.; HEBA A. SELIM, M.Sc.
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Recombinant Human Erythropoietin ◽  
Deficiency Anemia ◽  
Human Erythropoietin

scholarly journals Role of IV administered Iron sucrose with recombinant erythropoietin in the treatment of moderate and severe iron deficiency anemia in the third trimester of pregnancy

2019 ◽  
Vol 8 (8) ◽  
pp. 3332
Author(s):  
Namrita Sandhu ◽  
Sanjay Singh
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Control Group ◽  
Case Group ◽  
Recombinant Erythropoietin ◽  
Third Trimester ◽  
The Third ◽  
In Pregnancy

Background: Iron deficiency Anemia in pregnancy is one of the most common and intractable nutritional problems in the world today. The objective of this study was to investigate the therapeutic efficacy and safety of rHuEPO combined with IV iron sucrose, in the treatment of pregnant women in third trimester with moderate and severe iron deficiency anemia and whether addition of erythropoietin will increase the rate of rise of Hb without compromising on the safety of the therapy.Methods: 60 pregnant women in the third trimester, diagnosed as cases of moderate and severe iron deficiency anemia were enrolled in this study with 30 subjects in each of the 2 groups. Recombinant Erythropoietin 2000 IU s/c and Inj Iron sucrose 100 mg slow intravenously in 100 ml 0.9% NS over 1 hr on alternate days was administered to the case group and the control group was administered only iron sucrose slow IV in the same dose on alternate days till target Hb (11gm%) was reached. Efficacy measures were reticulocyte count, increase in Hb/week, time to target Hb level and need for continued therapy after 4 weeks.Results: In the case group, the increases in Hb were greater after 1 week of treatment and this was found to be significant (P < .01), the median duration of therapy was shorter in the case group (22 versus 34 days), with more patients reaching the target hemoglobin level by 4 weeks as opposed to 7 weeks in the control group. Average rise in Hb/week was much more in the case group. The groups did not differ with respect to maternal and fetal safety parameters.Conclusions: Iron sucrose plus rhEPO is an effective treatment for iron deficiency anemia in pregnancy probably because of a synergistic action, with rhEPO stimulating erythropoiesis and iron sucrose delivering iron for hemoglobin synthesis. 

COVID-19 in pregnant and non-pregnant women of early reproductive age

GYNECOLOGY ◽  
2021 ◽  
Vol 23 (3) ◽  
Author(s):  
Tatiana E. Belokrinitskaya ◽  
Nataly I. Frolova ◽  
Konstantin G. Shapovalov ◽  
Kristina A. Kolmakova ◽  
Ludmila I. Anohova ◽  
...  
Keyword(s):  
Risk Factors ◽  
Computed Tomography ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Clinical Manifestations ◽  
Reproductive Age ◽  
Deficiency Anemia ◽  
Third Trimester ◽  
The Third

Aim. To identify confounding factors, features of the clinical course and outcomes of COVID-19 in pregnant and non-pregnant patients of early reproductive age who have no known risk factors and premorbid background. Materials and methods. The study included 163 pregnant women in the third trimester of gestation, 100 non-pregnant women with laboratory-confirmed SARS-CoV-2 infection and 100 pregnant women who did not get sick. Patients of all groups were comparable in age (1835 years), social status, parity, body mass index, had no known risk factors for COVID-19; those who got sick were treated simultaneously. Results. Statistically significant associations were revealed between COVID-19 infection in the pregnant and iron deficiency anemia, vegetovascular dystonia, belonging to the Buryat ethnicity, and smoking. Pregnant women with COVID-19 were more likely to have no symptoms (23.3% vs 5%; p0.001) or had a mild course of the disease (58.9% vs 24%; p0.001). In non-pregnant patients, the course of infection was more often moderate (61% vs 14.7%; p0.001) or severe (10% vs 3.1%; p=0.038). Clinical manifestations of new coronavirus infection (NCV) in pregnant women were dominated by anosmia (87.7% vs 40%; p0.001), drowsiness (68.7% vs 17%; p0.001), dyspnea, even with a mild lung lesion (68.1% vs 19%; p0.001), headache (41.7% vs 24%; p=0.006), arthralgia (29.4% vs 16%; p=0.021), while fever above 38 C (7.4% vs 28%; p0.001) and cough (38.7% vs 61%; p0.001) were much less common. With computed tomography, pneumonia in pregnant women was diagnosed several times less often (21.4% vs 87.4%; p0.001). In the non-pregnant group, there was one death (1% vs 0%; p=0.201) associated with late hospitalization for severe NCI with grade 4 pulmonary involvement as shown on computed tomography. Conclusion. Confounders of COVID-19 in pregnant women who have no known risk factors in the third trimester of gestation are iron deficiency anemia, vegetovascular dystonia, belonging to the Buryat subpopulation, and smoking. In pregnant women, the main clinical symptoms of SARS-CoV-2 infection, with the exception of loss of smell, were nonspecific and characteristic of the physiological course of late gestation: drowsiness, dyspnea, joint pain. The predominance of mild or asymptomatic forms of infection, the lower incidence of pneumonia, and the absence of deaths in pregnant women suggests a more favorable course of COVID-19 NCI.

scholarly journals Lactoferrin Efficacy versus Ferrous Sulfate in Treatment of Children with Iron Deficiency Anemia

2021 ◽  
Vol 11 (01) ◽  
pp. e199-e204
Author(s):  
Osama Mahmoud El-Asheer ◽  
Ahmed Gaber Ahmed ◽  
Zainab AbdelAal Abdel Hafez ◽  
Marwa AbdelHafiz Dahpy ◽  
Amal AbdElSalam Soliman
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Patient Compliance ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Serum Iron ◽  
Deficiency Anemia ◽  
Serum Transferrin ◽  
Iron Binding ◽  
Clinical Benefits

AbstractLactoferrin (LF) is an iron-binding globular glycoprotein that is structurally and chemically similar to serum transferrin. Many studies have been done to evaluate the effect of oral LF administration on iron deficiency anemia (IDA) with controversial results. This study was designed to compare the efficacy of LF versus oral ferrous sulfate (OFS) therapy in the treatment of children with IDA. A significant increase in mean hemoglobin and serum iron concentrations was noted in the group that received oral bovine LF (11.06 ± 0.96 and 42.79 ± 6.14, respectively) versus the group that received OFS (10.24 ± 0.57 and 28.94 ± 5.05, respectively, with p < 0.001 for each) after 30 days of the treatment with fewer side effects (9.3 vs. 33.3% with p = 0.043). Oral bovine LF is a more effective and safer alternative in treating iron deficiency and IDA compared with OFS with clinical benefits of fewer side effects and better patient compliance.

Sign in / Sign up

Export Citation Format

Share Document